Evidence map›Paper›PMID 39937006›Full record

ArticleCells2025

Comprehensive Search for Genes Involved in Thalidomide Teratogenicity Using Early Differentiation Models of Human Induced Pluripotent Stem Cells: Potential Applications in Reproductive and Developmental Toxicity Testing.

Yu Kato, Takeshi Inaba, Koudai Shinke, Noriko Hiramatsu, Tetsuhiro Horie, Takuya Sakamoto, Yuko Hata, Eiji Sugihara, Tetsuya Takimoto, Noriaki Nagai and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Advances in Cytotoxicity Testing: From In Vitro Assays to In Silico Models.International journal of molecular sciences · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yu KatoOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0002-4337-6775
Takeshi InabaGraduate School of Health Sciences, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Koudai ShinkeGraduate School of Health Sciences, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Noriko HiramatsuCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Tetsuhiro HorieMedical Research Institute, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan.ORCID 0000-0002-2095-9425
Takuya SakamotoMedical Research Institute, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan.ORCID 0000-0003-2519-4510
Yuko HataOpen Facility Center, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Eiji SugiharaOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0002-3233-1045
Tetsuya TakimotoOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0009-0009-3008-8078
Noriaki NagaiFaculty of Pharmacy, Kindai University, Higashiosaka 577-8502, Osaka, Japan.ORCID 0009-0007-1266-038X
Yasuhito IshigakiMedical Research Institute, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan.ORCID 0000-0003-1012-8430
Hajime KojimaDepartment of Pharmaceutical Engineering, Faculty of Engineering, Sanyo-Onoda City University, Sanyo-Onoda 756-0884, Yamaguchi, Japan.
Osamu NaganoOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Naoki YamamotoCenter for Society-Academia Collaboration, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0002-9659-3204
Hideyuki SayaOncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0001-6610-1902

Funding

Japan Agency for Medical Research and Development JP24mk0101223
6 · The paper itself

Abstract

Developmental toxicity testing is essential to identify substances that may harm embryonic development. This study aimed to establish a protocol for evaluating developmental toxicity using human induced pluripotent stem cells (iPSCs) by analyzing cellular activity and gene expression changes. Two ICH S5(R3) positive substances, valproic acid (VPA), which is a substance previously detected as positive by other test methods, and thalidomide (Thalido), were examined during early trichoderm differentiation without fetal bovine serum. RNA-seq analysis identified seven candidate genes, including

Indexed as

Cell DifferentiationInduced Pluripotent Stem CellsReproductionTeratogenesisTeratogensThalidomideToxicity TestsHumansValproic AcidTeratogensThalidomideValproic Acidalternative testing methodscandidate genesdevelopmental toxicityICH S5(R3)iPSCsRNA-seq analysisthalidomidevalproic acid

Identifiers

PMID39937006
PMCPMC11817626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.